RxSight, Inc.

Case Overview
60 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 09/22/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: RxSight, Inc. |
Court: | Court: Central District of California |
Case Number: | Case Number: 8:25cv01596 |
Class Period: | Class Period: 11/07/2024 - 07/08/2025 |
Ticker: | Ticker: RXST |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of those who acquired RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ:RXST) securities during the period of November 7, 2024 through July 8, 2025, inclusive (“the Class Period”). Investors have until September 22, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in sales, utilization, and revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. The Company’s Chief Executive Officer, Ronald Kurtz attributed the lower sales to “adoption challenges over the last few quarters.” On this news, the price of RxSight shares declined by $4.84, or approximately 37.8%, to close at $7.95 per share on July 9, 2025.
The lawsuit alleges that RxSight failed to disclose to investors that: (1) the Company was experiencing “adoption challenges” and structural issues resulting in declines in sales and utilization; (2) RxSight had overstated the demand for its products; and (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025.